June 14, 2011 New research shows a drug commonly used to treat sickle cell anemia in adults reduces bouts of acute pain and a pneumonia-like illness, cuts hospitalization time and eases other symptoms of the disease in young patients. Results of the randomized, double-blind trial mark a dramatic advance in treatment of children with the inherited blood disorder.
"These results show that hydroxyurea has the potential to dramatically improve the quality of life for an entire generation of patients with sickle cell disease," said Winfred Wang, M.D., the study's principal investigator and a member of the St. Jude Children's Research Hospital Department of Hematology. He said the findings mean hydroxyurea should now be considered for treatment of all infant and toddlers with sickle cell anemia in hopes of preventing or delaying disease complications. The research will be published in the May 14 issue of the British medical journal The Lancet.
St. Jude researchers led the six-year Pediatric Hydroxyurea Phase III Clinical Trial, known as Baby HUG. The federally funded study involved 193 infants and toddlers enrolled at 13 participating U.S. medical centers and a coordinating center.
About 100,000 Americans have sickle cell anemia, a chronic disorder associated with a range of health problems, including an increased risk of strokes and premature death. Sickle cell anemia is the most common genetic disorder affecting Americans of African descent, but the disease also strikes persons of other racial and ethnic backgrounds.
Sickle cell anemia is caused by a gene mutation that leaves the red blood cells of sickle cell patients prone to assuming the stiff, crescent shape for which the disease is named. The misshapen cells can clog blood vessels, triggering pain crises, strokes and organ damage, including kidney failure. The drug works in part by increasing production of fetal hemoglobin, which counteracts the effects of the sickle hemoglobin. Fetal hemoglobin is the main hemoglobin produced by all newborns, but production normally decreases dramatically within a few months after birth.
While life expectancy for sickle cell anemia patients has improved in recent decades thanks in part to better supportive care, Wang said hydroxyurea is the first drug proven to reduce the incidence of a wide range of symptoms in extremely young sickle cell patients regardless of disease severity. The drug is inexpensive and easy to administer. The drug has been used for more than 15 years as a treatment for sickle cell disease with no evidence of serious side effects. Hydroxyurea began as a potential cancer treatment, but won U.S. Food and Drug Administration approval for use in adults with severe sickle cell disease. Baby HUG is the largest trial of hydroxyurea in much younger patients.
The Baby HUG trial was launched in 2003 after promising preliminary results regarding the drug's safety and effectiveness in extremely young children. The research included patients who were ages 9 to 18 months when they began the study. Participants were randomly assigned to receive either a standard dose of hydroxyurea or a placebo every day for two years. Neither the families nor the caregivers knew which children received hydroxyurea.
An analysis of 179 patients who completed at least 18 months of the study found children in the placebo group had nearly twice as many acute pain episodes, were three times more likely to suffer a pneumonia-like illness known as acute chest syndrome and five times more likely to develop painful swelling of the hands and feet called dactylitis. They were also slightly more likely to be hospitalized or need blood transfusions to ease sickle cell symptoms.
The most common side effect reported in this study was a mild-to-moderate drop in the white blood cells known as neutrophils, which occurred more often in children receiving hydroxyurea. Low neutrophil counts can be associated with an increased risk of infection, but there was no evidence of this in the Baby HUG trial.
Although results of kidney and spleen function tests were not significantly different between the Baby HUG treatment groups, Wang said other measures suggested that hydroxyurea might protect those organs as well as the brain and lungs from the chronic damage that leaves sickle cell anemia patients at increased risk for premature death. A follow-up study to Baby HUG is underway, focusing on possible long-term benefits from continued treatment with higher doses of hydroxyurea.
The study's other authors are Russell Ware, formerly of St. Jude; Lynn Wynn, of St. Jude; Scott Miller, SUNY Downstate Medical Center; Rathi Iyer, University of Mississippi Medical Center; James Casella, Johns Hopkins University School of Medicine; Caterina Minniti, Children's National Medical Center; Sohail Rana, Howard University College of Medicine; Courtney Thornburg, Duke University Medical Center; Zora Rogers, Southwestern Medical Center, Dallas; Ram Kalpatthi, Medical University of South Carolina; Julio Barredo and F. Daniel Armstrong, both of University of Miami; R. Clark Brown and Beatrice Files, both of Emory University School of Medicine; Sharada Sarnaik, Children's Hospital of Michigan; Thomas Howard, University of Alabama at Birmingham; Abdullah Kutlar, Medical College of Georgia; Jonathan Goldsmith and Myron Waclawiw, both of the National Heart, Lung, and Blood Institute (NHLBI); and Xiangke Huang and Bruce Thompson, both of the Clinical Trials and Surveys Corp.
NHLBI and the National Institute of Child Health and Human Development funded the research.
Other social bookmarking and sharing tools:
Note: Materials may be edited for content and length. For further information, please contact the source cited above.
- Winfred C Wang et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). The Lancet, Volume 377, Issue 9778, Pages 1663 - 1672, 14 May 2011 DOI: 10.1016/S0140-6736(11)60355-3
Note: If no author is given, the source is cited instead.